Sept 10 (Reuters) - The impact of U.S. President Donald

Trump's plan to levy import duties on pharmaceutical products

and his push to lower drug prices are likely to be manageable

for big U.S. and European drugmakers, according to an analysis

by brokerage Morningstar.

The report said the near term risk from the push to slash

prescription drug prices to match those paid overseas would be

"exceedingly low" as it could harm patient access to drugs.

In July, Trump had called on drugmakers to provide so-called

most-favored-nation prices to every patient enrolled in the

government Medicaid health program for low-income people, and to

guarantee such pricing for new drugs.

The report looked at ten major pharmaceutical firms in the

U.S. and Europe - AstraZeneca ( AZN ) , Novartis,

Sanofi, GSK, Novo Nordisk, AbbVie ( ABBV )

, Amgen ( AMGN ), Eli Lilly ( LLY ), Merck ( MRK ), and

Pfizer ( PFE ).

While all companies will likely need to pay higher taxes in

the long-term after relocating manufacturing to the U.S.,

European firms will also face elevated costs associated with new

facilities, the report said.

Several global drugmakers have pledged billions of dollars

to scale up their U.S. manufacturing capacity as the industry

braces for sector-specific tariffs.

Trump has said he would initially start small with pharma

tariffs and eventually hike it up to 250% in an effort to boost

domestic production.

The U.S. had also reached a bilateral trade deal with the

European Union in July, which includes a 15% tariff on

pharmaceuticals, except for some generic drugs.

Assuming an initial 15% U.S. tariff on pharmaceuticals, the

brokerage estimates the impact to peak at about 4% of core

profit on average, after mitigation efforts, for the companies

analyzed.